Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Label Revision Ordered for Acetaminophen to Add Drug-Induced Hypersensitivity Syndrome as ADR
January 19, 2023
- Label Expansions for Nubeqa, Rinvoq, Imbruvica on PAFSC Agenda for Feb. 1
January 19, 2023
- Chuikyo’s Drug Pricing Debate Slated to Begin in May after Expert Panel Proposal
January 19, 2023
- Emgality, Revestive, Veklury Brace for Price Cuts under CEA Scheme
January 19, 2023
- Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
- 5 Wholesalers to Be Slapped with 600 Million Yen Surcharges over Kyushu Bid-Rigging Case
January 18, 2023
- METI Aims at “1 or 2” Returns of Several 10s of Billions of Yen a Year from Biotech Ecosystem Program: Official
January 18, 2023
- HES Preparations Now Contraindicated in Patients with Severe Sepsis: Label Revisions
January 18, 2023
- Ex-Minister Tamura Hightlights Need for Rewarding Innovation towards FY2024 Drug Reform
January 17, 2023
- MHLW Panel to Discuss Semaglutide for Obesity, Precedex, Entyvio SC on Jan. 27
January 17, 2023
- Experts Call for Deregulations for Orphan Support, English Dossiers to Foster Biotech Ecosystem
January 16, 2023
- MHLW Panel OKs 64 More Health Damage Claims for COVID-19 Vaccines
January 16, 2023
- MHLW Panel Urges Better Application of Emergency Approval
January 16, 2023
- MHLW Likely to Give Up Submitting Bill to Lift Bans on Cannabis-Derived Drugs
January 13, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
- Japan Panel Recognizes 5 More Deaths Possibly Tied to COVID Vaccines
January 13, 2023
- PMP, Off-Patent Drug Rules to Be Major Topics for 2024 Reform: MHLW Pharma Management Director
January 12, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- 4 Cases of New COVID Variant XBB.1.5 Confirmed in Japan: Govt
January 12, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…